Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin human (Generex Biotechnology Corporation)
- Development stage
- Unknown
- Lead developer
- Generex Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Buccal
01
Overview
Oral-lyn (marketed as Oral Recosulin in India) is a buccal spray formulation of recombinant human insulin developed by Generex Biotechnology and licensed to Shreya Life Sciences. It utilizes the proprietary RapidMist device to deliver insulin to the buccal mucosa, where it is rapidly absorbed into the systemic circulation, bypassing the lungs and avoiding the need for subcutaneous injections. Designed for prandial (mealtime) glucose control, it targets the insulin receptor to facilitate glucose uptake in patients with type 1 and type 2 diabetes mellitus. The product was first approved and launched in India in 2008.
- Brand names
- Oral-lynOral Recosulin
- Other names
- buccal human insulinoral insulin sprayGenerex Oral-lyn
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin human (Generex Biotechnology Corporation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin human (Generex Biotechnology Corporation).